Historical perspective
Gaucher's disease was first described by Phil- lippe Gaucher in 1882, who reported a patient with hepatosplenomegaly in whom the characteristic abnormal macrophages were thought to represent a primary neoplasm of the spleen. 3 Identification of the stored material as glucocerebroside in 1934 was followed many years later by the finding that glucocerebrosidase activity was markedly reduced in the spleen of patients with Gaucher's disease by Brady et a14 and Patrick5 independently in 1965. Although the enzyme is deficient in most tissues of the body, it is the cellular specificity of the substrate that determines which tissues are principally affected. The substrate, glucocerebroside, is a constituent of complex glycolipids and is released in the breakdown of cell membranes, particularly leucocytes and erythrocytes, by mononuclear phagocytes. Thus, in Gaucher's disease engorged macrophages accumulate throughout the body and cause hepatosplenomegaly, bone marrow infiltration with skeletal disease, and, rarely, involvement of the lungs and brain.
Classification of Gaucher's disease There are three main clinical subtypes of Gaucher's disease. 6 Most patients suffer from visceral involvement in the absence of neurological disease: this non-neuronopathic form of the condition is known as type I Gaucher's disease. Within this group there is great variability in the rate of disease progression. Patients may present in childhood with hepatosplenomegaly, pancytopenia, bone necrosis, and osteoporosis or come to light in the ninth decade of life because of the incidental finding of splenomegaly. Type I Gaucher's disease occurs rarely in all ethnic groups but it is more frequent in the Ashkenazi Jewish population. A wide range of disease activity is seen in .he Jewish population but patients with late onset or mild disease are usually found to be of Ashkenazi descent.6 Type II (acute neuronopathic) disease is a rare disorder with no ethnic predilection. It causes a rapidly progressive neurovisceral storage disease and death in infancy. Affected infants come to light as a result of oculomotor abnormalities, cranial and bulbar nerve palsies, spasticity, convulsions, and opisthotonus. Type III (subacute neuronopathic) Gaucher's disease progresses less rapidly but is associated with ataxia, myoclonus, and convulsions; there is progressive intellectual impairment which is accompanied by hepatosplenomegaly and skeletal disease. Death usually occurs in childhood or adolescence. This type of Gaucher's disease is also rare but it is frequent in a genetic isolate that represents a single extended pedigree originating from the Norrbottnian region of northern Sweden.7 Diagnosis Typically the diagnosis of Gaucher's disease is established by the finding of characteristic glycolipid laden large macrophages on histological examination of bone marrow, the liver, or spleen.68 These findings are not absolutely specific since pseudo-Gaucher's cells may appear in the marrow of patients suffering from a variety of conditions associated with increased cell turnover, including chronic myeloid leukaemia and thalassaemia. The most widespread missense mutations responsible for Gaucher's disease N370S, L444P, and R463C (cDNA 1226G, 1448C and 1504T respectively) occur in residues at exons 9 and 10 which have been considered critical for the formation of the active site. However, other missense mutations occur throughout the gene (four in exon 5, two in exon 6, one in exon 7, five in exon 8, two in exon 11)182432 and our understanding of the part played by these residues in the functional integrity of human glucocerebrosidase will depend in the first instance on the determination of the three dimensional structure of the enzyme at atomic resolution.
Mutational analysis in clinical practice
The human glucocerebrosidase gene has been subject to intensive study in relation to Gaucher's disease. Given the prevalence of Gaucher's disease and the morbidity associated with its more severe forms, there is a need for methods to facilitate prenatal screening and diagnosis. The emergence of an effective alternative to marrow transplantation in the treatment for non-neuronopathic Gaucher's disease also has a bearing on diagnosis and prognosis. Although enzymatic assay of acid Pglucosidase activity may serve to confirm the diagnosis of Gaucher's disease when suspected, activities obtained in up to 20% of obligate heterozygotes are within the normal range of enzymatic activity. Under these circumstances, molecular analysis of the glucocerebrosidase gene should aid the definitive detection of carriers in families at risk for Gaucher's disease. In addition, procedures based on the polymerase chain reaction for the analysis of genomic DNA should improve the potential for early prenatal diagnosis by chorionic villus sampling where there has been experience of neuronopathic Gaucher's disease (figure).
Molecular analysis of the glucocerebrosidase gene is complicated by the presence of the transcribed pseudogene and thus methods to detect mutations must either amplify the structural gene sequences selectively or allow separation of the amplified structural gene from the amplified pseudogene sequences.2538 Screening for known mutations has relied on hybridisation to allele specific oligonucleotide probes or, more simply, when the mutation alters a restriction site, by digestion with appropriate restriction endonucleases. Examples of the latter include the NciI site associated with the L444P mutation,3' the HhaI site associated with the P415N mutation,39 and deletion of a CfrlO site in association with N463C. 25 However, most of the mutations that cause Gaucher's disease do not alter restriction sites and screening for these has been facilitated by the application of the 'mismatch PCR' technique.' The search for known mutations, regardless of whether or not a restriction site is present, has been further simplified by the use of the amplification refractory mutation system (ARMS) which permits rapid genotyping based on allele specific amplification in the PCR in the single step25 (figure). These procedures allow genetic diagnosis of Gaucher's disease to be carried out in diagnostic laboratories outside major research centres. In our laboratory, among seven Ashkenazi Jewish patients with Gaucher's disease, 11 disease alleles were identified as N370S, and two as .
K-
Prenatal diagnosis of the L444P mutation in the human glucocerebrosidase gene by ARMS analysis. The PCR was carried out simultaneously with a primer complementary to the wild type sequence (a) and the mutant sequence (b). The pseudogene, which normally carries the L444P sequence, gives rise to a 55 bp smaller product. I and 2 parents (first cousins); 3 affected child previously treated by bone marrow transplantation at the age of 2 years; 4 CVS: chorionic villous DNA obtained from a further pregnancy at 9 weeks' gestation. 5 DNA obtained from healthy daughter. The assignment of genotypes, including heterozygosity in the fetus, was later confirmed by digestion with the restriction endonuclease NciI.
84GG, leaving only one unknown allele. Among our other 17 patients from other ethnic backgrounds, ARMS analysis for common mutations showed six N370S alleles, nine L444P alleles, two N463C alleles, and one IVS2 + 1 leaving less than half the disease alleles in this diverse group of patients unidentified.
Population genetics
Gaucher's disease appears to be most common in Ashkenazi Jews in whom a recent survey has suggested that the frequency of homozygosity for mutations may be as high as 1 in 976.4' This is largely because of the prevalence of the N370S mutation which accounts for 75% of disease alleles.28 Other common mutations in this population are 84GG (13%), IVS2+ 1 (3%), leaving less than 5% of alleles unknown.3034 As a result of studies in more than 2000 Ashkenazi subjects, Beutler et a14' estimated the gene frequency for N370S and the 84GG mutation to be 0 032 and 0-00217, respectively; thus 1 in 980 offspring of unselected marriages between Ashkenazi Jews are predicted to be N370S homozygotes. In their survey, Beutler et al discovered four asymptomatic persons harbouring two copies of the N370S mutation when they examined a random Ashkenazi sample. The N370S mutation was found to be more prevalent than expected in the healthy Ashkenazi population in relation to a large sample of Ashkenazi patients with Gaucher's disease. Beutler et al estimated that approximately two-thirds of the alleles were missing from the patient population with Gaucher's disease, once again indicating variable expressivity of the homozygous form of this mutation and its association with relatively mild disease. This mutation exists at polymorphic frequency among Ashkenazi Jews and raises the possibility that it confers a selective advantage in the heterozygous state. The N370S and 84GG mutations are found consistently in the context of their respective haplotype associations, an observation that suggests that they arose on a single ancestral chromosome and were selected for or spread by diffusion from a single founding population. The Swedish isolate found in Norrbotten is strongly associated with type III Gaucher's disease.7 All 10 patients studied were found to be homozygous for L444P and careful pedigree analysis later showed that these subjects were descended from a common ancestor in northern Sweden.742 Among non-Jewish patients, L444P is the most common disease allele and accounts for approximately 40% of disease alleles. In the general population, L444P occurs in the context of different haplotypes, a finding that suggests that this pathological variant has arisen repeatedly as a result of distinct mutational events. 23 Genotype-phenotype correlations in Gaucher's disease Many inherited diseases show variable clinical expressivity and Gaucher's disease is no exception: type II (neuronopathic disease) is a condition of infancy that progresses rapidly to death whereas other persons homozygous for other mutations in the glucocerebrosidase gene may remain asymptomatic in their ninth decade of life. Striking heterogeneity of clinical expression may also be observed in full sibs within a given pedigree affected by Gaucher's disease and provides clear evidence that factors outside the glucocerebrosidase locus may also influence the degree to which the enzymatic deficiency is responsible for clinical manifesta-tions. In general, it may be said that the more severe the disease the lower the level of residual enzymatic activity that can be expected.
The level of activity needed to protect against the more severe manifestations of Gaucher's disease may be a small fraction of the normal. Conzelman and Sandhoffl" proposed that there exists a critical threshold in the activity of lysosomal enzymes below which accumulation of undegraded substrate occurs. This critical threshold and the rate of accumulation of undegraded substrate may differ between cells, that is, between Kupffer cells and splenic macrophages or between the same cells at different developmental stages in different tissues, depending on the rate of influx of substrate. Thus a very small difference of residual activity could markedly affect the age of onset of the disease, the rate of its progression, and its clinical manifestations. An additional factor in relation to Gaucher's disease is that, during its course, when the spleen reaches a critical size, hypersplenism may result in the dramatic increase in glycolipid turnover from blood cell membranes. This would be expected to accelerate the deposition of undegraded substrate. Thus secondary pathophysiological disturbances may influence the apparent severity of Gaucher's disease disproportionately and lead to bias in the correlation of given genotypes with clinical manifestations. Other mechanisms may influence the activity of glucocerebrosidase in Gaucher's cells: there may be enhanced transcription, resulting in a 2 to 3 fold increase in steady state mRNA that would partially compensate for decreased enzymatic activity'9 and partial amelioration of the disease.
Because of the implications for prognosis and counselling of carriers, an important objective in the molecular analysis of the glucocerebrosidase gene has been to correlate the nature of the mutation with the clinical features of the disease. As indicated above, precise correlation has been difficult to achieve in Gaucher's disease. Nevertheless, it is clear that genotype does influence phenotype strongly. Indices of disease severity, that is, age of presentation or a composite score based on other clinical criteria, have been used to estimate rates of disease progression." In general, homozygosity for the N370S mutation confers the mildest form of disease and, although the presence of another allele is usually associated with more aggressive features, expression of one copy of this mutated gene may indeed provide sufficient enzymatic activity to preclude development of neurological disease. Some homozygotes for N370S remain asymptomatic and have very few manifestations of the disease even on careful clinical study and, as indicated above, up to two-thirds of persons with this genotype may escape medical attention for Gaucher's disease.4' Among those who present with symptoms, the median age of detection is 30 years but a few subjects have a disease with onset in adolescence or early adult life. In one such case the presence of a deleted allele resulting in incorrect assignment of a homozygous genotype was later shown. 48 Thus, in any individual patient it is difficult to predict accurately the outcome of disease solely from knowledge of the genotype. To determine the origin of phenotypic variation is a scientific question of importance which may eventually lead to therapeutic approaches to disease modification, for example, in relation to the sphingolipid activator protein. The investigation of the source of phenotypic variation will be greatly helped by the development of methods to measure residual glucocerebrosidase activity in situ and this might be achieved by loading lysosomes in macrophages obtained from patients with Gaucher's disease with radiolabelled glucocerebroside or a suitable fluorescent artificial substrate. 49 This would in the first place allow the hypothesis of Conzelman and SandhoffV3 to be examined. In the same way, the production of models of Gaucher's disease in experimental animals50 may also assist in the investigation of the cellular pathophysiology of glucocerebrosidase deficiency in man.
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